ABUS
Arbutus Biopharma Corp
4.90$
-0.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +11.3% | +85.4% | +85.6% | +7.6% | -7.0% | -2.5% | -11.4% | -18.6% | -1.6% | -1.7% | -73.7% | |
| – | +573.0% | +77.2% | -61.4% | -58.7% | +8.9% | -9.4% | +4.3% | +11.8% | +29.5% | -3.4% | -22.6% | |
| – | -20,331.3% | – | -90.6% | -128.5% | – | -94.6% | -31.4% | -19.3% | – | – | – | |
| – | -188.6% | – | – | -235.8% | – | – | +115.8% | +3,044.4% | -162.3% | – | – | |
| – | +116.6% | +74.7% | +81.8% | -84.3% | -48.2% | -61.1% | +253.3% | -36.7% | +96.9% | -81.9% | -100.0% | |
| – | – | -1,390.3% | – | -114.7% | – | -152.6% | -15.0% | +491.1% | – | -54.8% | -32.1% | |
| – | – | – | – | – | +10.5% | +8.7% | +0.1% | – | – | – | – | |
| – | +137.1% | -99.6% | +7,642.9% | +37.2% | -72.0% | +358.8% | +58.2% | -92.0% | – | – | – | |
| – | +0.0% | +0.0% | -200.0% | +0.0% | – | – | – | – | – | – | – | |
| – | +137.1% | -91.2% | +290.1% | +12.8% | -32.6% | +131.6% | +58.2% | -76.8% | -3.7% | +69.7% | -89.0% | |
| – | +2,626.0% | -251.6% | – | -156.3% | – | – | +178.9% | -237.7% | – | – | -282.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.